TY - JOUR
T1 - Detection of SARS-CoV-2 peptide-specific antibodies in Syrian hamster serum by ELISA
AU - Quach, Huy Quang
AU - Ovsyannikova, Inna G.
AU - Poland, Gregory A
AU - Kennedy, Richard B.
N1 - Funding Information:
This work was supported by Mayo Clinic funding provided to Dr. Kennedy for SARS-CoV-2 research. Grant funding from ICW Ventures for preclinical studies on a peptide-based COVID-19 vaccine is also acknowledged. We also thank Dr. Bryan H. Bellaire at Iowa State University for providing us sera from SARS-CoV-2-infected hamsters.
Funding Information:
Dr. Poland is the chair of a Safety Evaluation Committee for novel investigational vaccine trials being conducted by Merck Research Laboratories. Dr. Poland offers consultative advice on vaccine development to Merck & Co. Inc., Avianax, Adjuvance, Valneva, Medicago, Sanofi Pasteur, GlaxoSmithKline, and Emergent Biosolutions. Drs. Poland and Ovsyannikova hold three patents related to measles and vaccinia peptide research. Dr. Kennedy holds a patent on vaccinia peptide research. Dr. Kennedy has received funding from Merck Research Laboratories to study waning immunity to measles and mumps after immunization with the MMR-II® vaccine. Drs. Poland, Kennedy, and Ovsyannikova have received grant funding from ICW Ventures for preclinical studies on a peptide-based COVID-19 vaccine. This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and was conducted in compliance with Mayo Clinic Conflict of Interest policies.
Funding Information:
This work was supported by Mayo Clinic funding provided to Dr. Kennedy for SARS-CoV-2 research. Grant funding from ICW Ventures for preclinical studies on a peptide-based COVID-19 vaccine is also acknowledged. We also thank Dr. Bryan H. Bellaire at Iowa State University for providing us sera from SARS-CoV-2-infected hamsters. Dr. Poland is the chair of a Safety Evaluation Committee for novel investigational vaccine trials being conducted by Merck Research Laboratories. Dr. Poland offers consultative advice on vaccine development to Merck & Co. Inc. Avianax, Adjuvance, Valneva, Medicago, Sanofi Pasteur, GlaxoSmithKline, and Emergent Biosolutions. Drs. Poland and Ovsyannikova hold three patents related to measles and vaccinia peptide research. Dr. Kennedy holds a patent on vaccinia peptide research. Dr. Kennedy has received funding from Merck Research Laboratories to study waning immunity to measles and mumps after immunization with the MMR-II? vaccine. Drs. Poland, Kennedy, and Ovsyannikova have received grant funding from ICW Ventures for preclinical studies on a peptide-based COVID-19 vaccine. This research has been reviewed by the Mayo Clinic Conflict of Interest Review Board and was conducted in compliance with Mayo Clinic Conflict of Interest policies.
Publisher Copyright:
© 2022 Elsevier B.V.
PY - 2022/6
Y1 - 2022/6
N2 - Golden Syrian hamsters are increasingly used as a permissive animal model for SARS-CoV-2 virus studies, but the lack of immunological assays and other immunological reagents for hamsters limits its full potential. Herein, we developed an ELISA method to detect antibodies specific to peptides and proteins derived from SARS-CoV-2 virus in immunized golden Syrian hamsters. Under optimized conditions, this assay quantitates antibodies specific for individual viral peptides, peptide pools, and proteins. Hence, this ELISA method allows investigators to quantitatively assess humoral immune responses at the peptide and protein levels and has potential application in the development of peptide-based vaccines to be tested in hamsters.
AB - Golden Syrian hamsters are increasingly used as a permissive animal model for SARS-CoV-2 virus studies, but the lack of immunological assays and other immunological reagents for hamsters limits its full potential. Herein, we developed an ELISA method to detect antibodies specific to peptides and proteins derived from SARS-CoV-2 virus in immunized golden Syrian hamsters. Under optimized conditions, this assay quantitates antibodies specific for individual viral peptides, peptide pools, and proteins. Hence, this ELISA method allows investigators to quantitatively assess humoral immune responses at the peptide and protein levels and has potential application in the development of peptide-based vaccines to be tested in hamsters.
KW - COVID-19 vaccine
KW - ELISA
KW - Golden Syrian hamsters
KW - Peptide-based vaccine
KW - SARS-CoV-2
UR - http://www.scopus.com/inward/record.url?scp=85128547370&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85128547370&partnerID=8YFLogxK
U2 - 10.1016/j.jim.2022.113275
DO - 10.1016/j.jim.2022.113275
M3 - Article
C2 - 35439529
AN - SCOPUS:85128547370
VL - 505
JO - Journal of Immunological Methods
JF - Journal of Immunological Methods
SN - 0022-1759
M1 - 113275
ER -